BridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Viewpoint - The article discusses an ongoing legal situation involving Pfizer's Vyndamax patent, focusing on two main aspects: infringement and validity of the patent, with a particular emphasis on infringement claims against generic manufacturers [1][2]. Group 1: Legal Context - The trial centers around Pfizer's defense of its Vyndamax patent estate, which is expected to be protected until 2035 [1]. - There are two key battlegrounds in the trial: infringement and validity, with current discussions leaning more towards the infringement aspect [2]. Group 2: Infringement Details - The case appears to be relatively clear regarding infringement, although it has been a point of controversy in recent months [2]. - Pfizer's claims involve the low-free energy polymorph of the drug, which is the form that is protected against generic manufacturers [2].